Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts
29. Juli 2024 08:25 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, July 29, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today responded to the undefined...
Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market to surpass US$ 211.3 Mn globally by 2027, Says CMI
30. April 2020 08:32 ET
|
CMI
SEATTLE, April 30, 2020 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global methicillin resistant Staphylococcus aureus (MRSA) testing systems market is estimated to be valued at...